HCV Product Pipeline

 DiscoveryPreclinicalPhase 1Phase 2Phase 3
 Discovery Preclinical Phase 1 Phase 2 Phase 3
ACH-3102NS5A Inhibitor    
ACH-2684NS3/4A Protease Inhibitor   
SovaprevirNS3/4A Protease Inhibitor    
ACH-3422Nucleotide NS5B Polymerase Inhibitor   

About Achillion

Headquartered in New Haven, CT, Achillion is a leading-edge pharmaceutical company advancing multiple candidates with proven mechanisms for the treatment of HCV. Click here for more information about Achillion's ongoing clinical trials.

HCV Education

About the Hepatitis C Virus

Hepatitis C is a worldwide epidemic affecting more than 170 million individuals. Click to learn more about this disease.

No upcoming events at this time.

You are now leaving this website. If you would like to continue, click Continue.